Pardes Biosciences (Pardes Biosciences) Interest Expense : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pardes Biosciences's interest expense for the three months ended in Jun. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pardes Biosciences's Operating Income for the three months ended in Jun. 2023 was $ -12.62 Mil. Pardes Biosciences's Interest Expense for the three months ended in Jun. 2023 was $ 0.00 Mil. Pardes Biosciences has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Pardes Biosciences Interest Expense Historical Data

The historical data trend for Pardes Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pardes Biosciences Interest Expense Chart

Pardes Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Interest Expense

-0.03

Pardes Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Interest Expense	Get a 7-Day Free Trial					-	-	-	-	-

Pardes Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Pardes Biosciences (NAS:PRDS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pardes Biosciences's Interest Expense for the three months ended in Jun. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2023 was $-12.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was $0.00 Mil.

Pardes Biosciences's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Pardes Biosciences had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Pardes Biosciences Inc has no debt.

Pardes Biosciences (Pardes Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008

Website

https://www.pardesbio.com

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.

Executives

Fs Development Holdings Ii, Llc	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky	officer: Chief Commercial Officer	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans	director, officer: Chief Executive Officer
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr	director	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone	director	190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson	officer: Chief Financial Officer	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth	officer: Chief Business & Strategy Ofcr	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney	officer: Chief Development Officer	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold	officer: Chief Scientific Officer	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin	director, officer: President and CEO	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013